[HTML][HTML] Review of cancer from perspective of molecular

SH Hassanpour, M Dehghani - Journal of cancer research and practice, 2017 - Elsevier
Cancer in the broader sense refers to more than 277 different types of cancer disease.
Scientists have identified different stage of cancers, indicating that several gene mutations …

Stem cell factor receptor/c-Kit: from basic science to clinical implications

J Lennartsson, L Rönnstrand - Physiological reviews, 2012 - journals.physiology.org
Stem cell factor (SCF) is a dimeric molecule that exerts its biological functions by binding to
and activating the receptor tyrosine kinase c-Kit. Activation of c-Kit leads to its …

Pericyte–fibroblast transition promotes tumor growth and metastasis

K Hosaka, Y Yang, T Seki, C Fischer… - Proceedings of the …, 2016 - National Acad Sciences
Vascular pericytes, an important cellular component in the tumor microenvironment, are
often associated with tumor vasculatures, and their functions in cancer invasion and …

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

M Abbaspour Babaei, B Kamalidehghan… - Drug design …, 2016 - Taylor & Francis
c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form
of c-Kit plays a crucial role in occurrence of some cancers. The function of c-Kit has led to the …

Oncogenes and cancer

CM Croce - New England journal of medicine, 2008 - Mass Medical Soc
This review—the first in a series concerning the biology of cancer—is a comprehensive
survey of oncogenes, tumor-suppressor genes, and microRNA genes in cancer cells. Work …

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial

MG Kris, RB Natale, RS Herbst, TJ Lynch Jr, D Prager… - Jama, 2003 - jamanetwork.com
ContextMore persons in the United States die from non–small cell lung cancer (NSCLC)
than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral …

In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth …

DB Mendel, AD Laird, X Xin, SG Louie… - Clinical cancer …, 2003 - AACR
One challenging aspect in the clinical development of molecularly targeted therapies, which
represent a new and promising approach to treating cancers, has been the identification of a …

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

R Capdeville, E Buchdunger, J Zimmermann… - Nature reviews Drug …, 2002 - nature.com
In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg,
Mariano Barbacid and many others in identifying cancer-causing genes in humans was …

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population‐based study in western …

B Nilsson, P Bümming, JM Meis‐Kindblom, A Odén… - Cancer, 2005 - Wiley Online Library
BACKGROUND Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and
their pathogenesis have redefined diagnostic criteria and have led to the development of …

Sunitinib: from rational design to clinical efficacy

LQM Chow, SG Eckhardt - Journal of clinical oncology, 2007 - ascopubs.org
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent
antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and …